TY - JOUR
T1 - Immune modulation via T regulatory cell enhancement
T2 - disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)
AU - Roth-Walter, F
AU - Adcock, I M
AU - Benito-Villalvilla, C
AU - Bianchini, R
AU - Bjermer, L
AU - Boyman, O
AU - Caramori, G
AU - Cari, L
AU - Chung, K F
AU - Diamant, Z
AU - Eguiluz-Gracia, I
AU - Knol, E F
AU - Kolios, Aga
AU - Levi-Schaffer, F
AU - Nocentini, G
AU - Palomares, O
AU - Redegeld, F
AU - Van Esch, B
AU - Stellato, C
N1 - Funding Information:
The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States‐Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014‐52706‐R and SAF2017‐84978‐R).
Funding Information:
The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Universit? e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States-Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606-B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014-52706-R and SAF2017-84978-R).
Publisher Copyright:
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2021/1
Y1 - 2021/1
N2 - Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.
AB - Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.
KW - adoptive cell therapies
KW - allergy
KW - autoimmunity
KW - CAR-Treg cells
KW - immunoregulation
UR - http://www.scopus.com/inward/record.url?scp=85098846922&partnerID=8YFLogxK
U2 - 10.1111/all.14478
DO - 10.1111/all.14478
M3 - Article
C2 - 32593226
SN - 0105-4538
VL - 76
SP - 90
EP - 113
JO - Allergy
JF - Allergy
IS - 1
ER -